Agile Therapeutics Announces Results of its Pre-Submission Meeting with FDA
11 avr. 2017 07h00 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., April 11, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women’s healthcare company, today announced it has received the final meeting minutes from its recent...
Agile Therapeutics Announces a Poster Presentation of its SECURE Phase 3 Study at the Contraceptive Technology 2017 Conference
16 mars 2017 16h30 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., March 16, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women’s healthcare company, announced a poster presentation of data from the SECURE Phase 3 clinical...
Agile Therapeutics to Present at 29th Annual ROTH Conference
01 mars 2017 16h10 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., March 01, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX) a women’s health specialty pharmaceutical company announced today that its Chief Executive Officer, Al...
Agile Therapeutics to Present at the RBC Capital Markets 2017 Global Healthcare Conference
14 févr. 2017 16h00 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Feb. 14, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX) a women’s health specialty pharmaceutical company, announced today that its Chief Executive Officer, Al...
Agile Therapeutics to Present at the 2017 BIO CEO & Investor Conference
02 févr. 2017 16h15 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Feb. 02, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX) a women’s health specialty pharmaceutical company, announced today that its Chief Executive Officer, Al...
Agile Therapeutics Announces Positive Top-line Phase 3 Results
03 janv. 2017 16h11 HE
|
Agile Therapeutics, Inc.
Resubmission of Twirla® New Drug Application Expected to Address FDA’s Complete Response LetterCompany Plans to Resubmit NDA in First Half of...
Agile Therapeutics to Present at Biotech Showcase 2017
22 déc. 2016 08h00 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Dec. 22, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX) announced today that its Chief Executive Officer, Al Altomari will present at the Biotech Showcase 2017 on...
Agile Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference
22 déc. 2016 07h30 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Dec. 22, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX) a women’s health specialty pharmaceutical company, announced today that its Chief Executive Officer, Al...
Agile Therapeutics Receives Approximately $3 Million in Non-Dilutive Funding from New Jersey’s Technology Business Tax Certificate Transfer Program
01 déc. 2016 08h00 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Dec. 01, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women’s health specialty pharmaceutical company announced today that it has received net proceeds of...
Agile Therapeutics Reports Third Quarter 2016 Financial Results and Announces Completion of Subject Visits for Twirla® Phase 3 SECURE Clinical Trial
07 nov. 2016 16h10 HE
|
Agile Therapeutics, Inc.
Top-Line Data Expected in Early January 2017; Resubmission Planned for First Half 2017 Cash Expected to Fund Operations Through the End of 2017 PRINCETON, N.J., Nov. 07, 2016 (GLOBE...